openPR Logo
Press release

Psoriasis Clinical Trial Pipeline: 80+ Companies Shaping the Future of Treatment

02-26-2025 04:13 PM CET | Health & Medicine

Press release from: DelveIinsight Business Research

Psoriasis Clinical Trial Pipeline

Psoriasis Clinical Trial Pipeline

Leading pharmaceutical companies are driving innovation in the psoriasis treatment pipeline, unlocking new growth opportunities for the future of care.

DelveInsight's 'Psoriasis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Psoriasis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Psoriasis pipeline domain.

For Psoriasis emerging drugs, the Psoriasis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Psoriasis Pipeline Report
• DelveInsight's Psoriasis Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline drugs for Psoriasis treatment.
• The leading Psoriasis companies include Soligenix, Artax Biopharma Inc, Huabo Biopharm Co., Ltd., SFA Therapeutics, Taizhou Mabtech Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Arctic Bioscience, Hansoh BioMedical R&D Company, Beijing InnoCare Pharma Tech Co., Ltd., Boehringer Ingelheim, Amgen, Janssen-Cilag International NV, Livzon Pharmaceutical Group Inc., Janssen Research & Development, LLC, Ganzhou Hemay Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., BioRay Pharmaceutical Co., Ltd., Takeda, Janssen Pharmaceutical K.K., Can-Fite BioPharma, Abbvie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, UCB Inc., LEO Pharma, Promius Pharma, Mayne Pharma, MC2 Therapeutics, Allergan, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, Genentech, Mylan, Biocad, Celltrion, Coherus BioSciences, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others are evaluating their lead assets to improve the Psoriasis treatment landscape.
• Key Psoriasis pipeline therapies in various stages of development include Topical roflumilast, GSK2982772, Hypericin, AX-158, HB0017 Q4W, SFA002, CMAB015, BMS-986165, HRO350, HS-10374, ICP-488, BI 765250, Apremilast, Guselkumab, LZM012, Guselkumab, Hemay005, TQH3906, Guselkumab, TQH2929, BR201, TAK-279, JNJ-77242113, piclidenoson, and others.
• In December 2024, Celltrion announced that its biosimilar Ustekinumab-stba (Steqeyma) received FDA approval for subcutaneous injection or intravenous infusion. It is approved for the treatment of adult and pediatric patients with plaque psoriasis, arthritis, and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis.
• On October 14, 2024, Dong-A-ST announced that its Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, received FDA approval for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stelara, a blockbuster drug developed by Janssen Biotech, generated $10.86 billion in sales globally in 2023, and Imuldosa's approval as a biosimilar offers a more cost-effective alternative for patients requiring long-term therapy for autoimmune conditions.

Request a sample and discover the recent breakthroughs happening in the Psoriasis pipeline landscape @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriasis Overview
Psoriasis is a chronic inflammatory skin disorder driven by a combination of genetic, environmental, and immune system factors. This non-contagious dermatological condition affects approximately 2% of the global population, with its severity varying among individuals. The extent of skin involvement can range from mild (10%). Among its different forms, chronic plaque psoriasis (psoriasis vulgaris) is the most prevalent. The disease is characterized by an immune response involving dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes, which contribute to the formation of skin lesions. For individuals with mild to moderate psoriasis, topical therapies remain the primary treatment approach.

Find out more about Psoriasis medication @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriasis Treatment Analysis: Drug Profile
Topical Roflumilast: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small-molecule inhibitor targeting phosphodiesterase type 4 (PDE4), an intracellular enzyme that plays a key role in inflammation by promoting pro-inflammatory mediators while reducing anti-inflammatory signals. PDE4 has been implicated in several inflammatory conditions, including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). Currently, roflumilast is in Phase III clinical development for the treatment of plaque psoriasis.

GSK2982772: GlaxoSmithKline
GSK2982772 is a selective ATP-competitive inhibitor of receptor-interacting protein-1 (RIP1) kinase (RIPK1), with an IC50 value of 16 nM. By specifically targeting RIP1, the molecule effectively blocks numerous TNF-dependent cellular responses. RIP1 is recognized as a key upstream kinase involved in regulating inflammation through both scaffolding and kinase-specific mechanisms. GSK2982772 is currently in Phase I clinical development for the treatment of psoriasis.

Key Psoriasis Therapies and Companies
• Topical roflumilast: Arcutis Biotherapeutics
• GSK2982772: GlaxoSmithKline
• Hypericin: Soligenix,
• AX-158: Artax Biopharma Inc,
• HB0017 Q4W: Huabo Biopharm Co., Ltd.,
• SFA002: SFA Therapeutics,
• CMAB015: Taizhou Mabtech Pharmaceutical Co., Ltd.,
• BMS-986165: Bristol-Myers Squibb,
• HRO350: Arctic Bioscience,
• HS-10374: Hansoh BioMedical R&D Company,
• ICP-488: Beijing InnoCare Pharma Tech Co., Ltd.,
• BI 765250: Boehringer Ingelheim,
• Apremilast: Amgen,
• Guselkumab: Janssen-Cilag International NV,
• LZM012: Livzon Pharmaceutical Group Inc.,
• Guselkumab: Janssen Research & Development, LLC,
• Hemay005: Ganzhou Hemay Pharmaceutical Co., Ltd.,
• TQH3906: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.,
• Guselkumab: Janssen Research & Development, LLC,
• TQH2929: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.,
• BR201: BioRay Pharmaceutical Co., Ltd.,
• TAK-279: Takeda,
• JNJ-77242113: Janssen Pharmaceutical K.K.,
• piclidenoson: Can-Fite BioPharma.

Learn more about the novel and emerging Psoriasis pipeline therapies @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriasis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Psoriasis Pipeline Report
• Coverage: Global
• Key Psoriasis Companies: Alcon, Seikagaku Corporation, Huons, Aramis Biosciences, Invirsa, Inc., IVIEW Therapeutics, Seinda Pharmaceutical, Serentrix, EyeD Pharma, SELAGINE, Theratome Bio, Alchemedicine, Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree/RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon/Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Mitotech, Senju Pharmaceutical, Sylentis, S.A./PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, AxeroVision, Inc., OKYO Pharma, Glaukos Corporation, Oculis, and others
• Key Psoriasis Pipeline Therapies: PL9643, Reproxalap, RGN-259 (Tß4), Tavilermide (MIM-D3), AR-15512, BRM421, SI-614, SkQ1 eye drops, SJP-0132, Tivanisiran (SYL1001), ST-100 (Vezocolmitide), VVN001, Tanfanercept Ophthalmic Solution/HL036, RP101, AXR-270 (cream), OK-101, AXR-270, AXR-159, GLK-301 (Pilocarpine Ophthalmic Topical Cream), Licaminlimab (OCS-02), and others.

Dive deep into rich insights for drugs used for Psoriasis treatment; visit @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Psoriasis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Psoriasis Pipeline Therapeutics
6. Psoriasis Pipeline: Late-Stage Products (Phase III)
7. Psoriasis Pipeline: Late-Stage Products (Phase III)
8. Psoriasis Pipeline: Mid-Stage Products (Phase II)
9. Psoriasis Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Psoriasis Clinical Trial Pipeline: 80+ Companies Shaping the Future of Treatment here

News-ID: 3888539 • Views:

More Releases from DelveIinsight Business Research

Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, Latest Drug Approvals | DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera Biosciences, Inc, Merck Sharp & Dohme LLC
Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, …
DelveInsight's "Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Novo Nordisk, AstraZeneca, Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotech
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PCSK9 Inhibitors pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "PCSK9 Inhibitors Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PCSK9 Inhibitors Market. The PCSK9
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharma, Tavanta Therapeutics, Candel Therapeutics
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Prostate Cancer pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Metastatic Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsight Report | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt, Cali Pharma
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsig …
DelveInsight's "Bunion Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast https://www.delveinsight.com/sample-request/hallux-valgus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Bunion

All 5 Releases


More Releases for Pharma

Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031. The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the